Medipharm Labs Corp T.LABS

Medipharm Labs Big Win

[Solid1]

One thing is clear! Medipharm Labs has had a clear competitive advantage in Germany since the change in the law. Since April 1, cannabis finished medicinal products have taken precedence over cannabis flowers (further justification is required for cannabis flowers)  

Finished medicinal products must be produced according to pharmaceutical standards, which Medipharm Labs does and is recognized for this by its licenses... This company is so brutally undervalued 

 

 

[QContinuum1]

The same has been said about Australia for quite some time and yet Medipharm has yet to benefit from those stricter production standards. I see all of that/this as good for Medipharm as well, but it's the transition to monetizing those catalysts that seems to be lacking here.  This is the reason the business is undervalued; nobody believe they can do it and they haven't proven thus

[alleyesonme]

Yes, lower revenue products are being replaced with higher revenue offerings, this year pharmaceutical API (dronabinol) comprises 10% of revenue, New B2B contracts signed for increases from almost nothing to close to 900k last quarter, costs have systematically dropped two years straight. I'm pleased with the focus on international medica and API, Canadian rec market is a joke, the gov is

[QContinuum1]

I would agree that the last Q or so highlighted some positive things. But, when those positive things had essentially nothing to do with the massive catalysts that the business had apparently been waiting on, then something doesn't jive.  There was never any indication that B2B or Drob was going to represent a significant uptick and thus I don't think anyone should take those lines

[CADInvestor12]

they did indicate B2B & Dronabinol impact .. taken directly from Q4 transcript ...  "we have seen renewed interest regarding B2B quality-focused manufacturing opportunity. Together, these deals could represent over $10 million in annual revenue potential."  "The most exciting development in Germany in Q4 was the commercialization of our natural Dronabinol product

[QContinuum1]

Certainly they made mention of those two, but it wasn't a strategic focus and neither really were on the radar up until that point.  Sometimes things falling into your lap is a great thing, that said, until the drob business can be backed up by sustainable and concrete POs/long term supply agreements, that revenue kicker can go as quickly as it came.  If Medipharm is the only game in

[Solid1]

Wait and see, dronabinol is a finished medicinal product and since these are to be prescribed preferentially in Germany and no longer fall under the Narcotics Act, the demand for them will increase. Consultation with health insurance companies has also led to many doctors being reluctant to prescribe cannabis, and this no longer exists either 

[alleyesonme]

Only two quarters so far of dronabinol sales, but still 10% of total revenue which didn't exist 2023, I'd imagine this would only grow considering the benefits cost wise and patient preference / shift to natural vs synthetic, perhaps an entry into the U.S with dronabinol?....epidiolex generic could be sooner than anyone thinks...Keith did say they're"busy preparing for epidiolex